IKK inhibitor suppresses epithelial-mesenchymal transition and induces cell death in prostate cancer
- PMID: 27432067
- DOI: 10.3892/or.2016.4915
IKK inhibitor suppresses epithelial-mesenchymal transition and induces cell death in prostate cancer
Abstract
IκB kinase (IKK)/nuclear factor κB (NF-κB) pathway activation is a key event in the acquisition of invasive and metastatic capacities in prostate cancer. A potent small-molecule compound, BMS-345541, was identified as a highly selective IKKα and IKKβ inhibitor to inhibit kinase activity. This study explored the effect of IKK inhibitor on epithelial-mesenchymal transition (EMT), apoptosis and metastasis in prostate cancer. Here, we demonstrate the role of IKK inhibitor reducing proliferation and inducing apoptosis in PC-3 cells. Furthermore, BMS345541 inhibited IκBα phosphorylation and nuclear level of NF-κB/p65 in PC-3 cells. We also observed downregulation of the N-cadherin, Snail, Slug and Twist protein in a dose-dependent manner. BMS‑345541 induced upregulation of the epithelial marker E-cadherin and phosphorylated NDRG1 at protein level. Moreover, BMS‑345541 reduced invasion and metastasis of PC-3 cells in vitro. In conclusion, IKK has a key role in both EMT and apoptosis of prostate cancer. IKK inhibitor can reverse EMT and induce cell death in PCa cells. IKK was identified as a potential target structure for future therapeutic intervention in PCa.
Similar articles
-
Targeting IκappaB kinases for cancer therapy.Semin Cancer Biol. 2019 Jun;56:12-24. doi: 10.1016/j.semcancer.2018.02.007. Epub 2018 Feb 24. Semin Cancer Biol. 2019. PMID: 29486318 Free PMC article. Review.
-
Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.Theranostics. 2018 Sep 9;8(17):4633-4648. doi: 10.7150/thno.26687. eCollection 2018. Theranostics. 2018. PMID: 30279728 Free PMC article.
-
Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells.Oncogene. 2006 Jan 19;25(3):387-98. doi: 10.1038/sj.onc.1209066. Oncogene. 2006. PMID: 16170348
-
Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.Mol Cancer Ther. 2016 Jul;15(7):1504-14. doi: 10.1158/1535-7163.MCT-15-0999. Epub 2016 Apr 8. Mol Cancer Ther. 2016. PMID: 27196761 Free PMC article.
-
Regulation and function of IKK and IKK-related kinases.Sci STKE. 2006 Oct 17;2006(357):re13. doi: 10.1126/stke.3572006re13. Sci STKE. 2006. PMID: 17047224 Review.
Cited by
-
Serum amyloid A1 mediates myotube atrophy via Toll-like receptors.J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):103-119. doi: 10.1002/jcsm.12491. Epub 2019 Aug 23. J Cachexia Sarcopenia Muscle. 2020. PMID: 31441598 Free PMC article.
-
Restoring E-cadherin Expression by Natural Compounds for Anticancer Therapies in Genital and Urinary Cancers.Mol Ther Oncolytics. 2019 May 17;14:130-138. doi: 10.1016/j.omto.2019.04.005. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31194121 Free PMC article. Review.
-
Targeting IκappaB kinases for cancer therapy.Semin Cancer Biol. 2019 Jun;56:12-24. doi: 10.1016/j.semcancer.2018.02.007. Epub 2018 Feb 24. Semin Cancer Biol. 2019. PMID: 29486318 Free PMC article. Review.
-
Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors.Cells. 2018 Aug 23;7(9):115. doi: 10.3390/cells7090115. Cells. 2018. PMID: 30142927 Free PMC article. Review.
-
Advances in Immunosuppressive Agents Based on Signal Pathway.Front Pharmacol. 2022 May 26;13:917162. doi: 10.3389/fphar.2022.917162. eCollection 2022. Front Pharmacol. 2022. PMID: 35694243 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials